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SELECTION OF THE MONTH 
Big Title: Population burden of alcoholic cirrhosis is related to daily alcohol 
consumption 
Small titles: Late viral hepatitis diagnosis – a missed opportunity, Testosterone: a 
novel approach to treat sarcopenia in male cirrhotics 
 
LIVER FIBROSIS 
Involvement of cartilage oligomeric matrix protein (COMP) 
COMP which is known to interact with other extracellular matrix (ECM) proteins such 
as the collagens and fibronectin, is expressed in different fibrotic tissues such as 
cirrhotic livers, among others. Magdaleno et al. now show that COMP contributes to 
liver fibrosis by regulating the deposition of fibrillary collagen-I, a major ECM 
component, via aCD36 (known as platelet glycoprotein 4)-dual specificity 
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mitogen-activated protein kinase kinase 1/2 (known as MEK1/2)-phospho-
ERK1/2 module. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Novel tumor-promoting signals, “non-canonical” induction of interferon (IFN)-
stimulated genes (ISGs), portal vein tumor thrombosis (PVTT) and liver resection 
The 14-3-3 proteins are a family of 28-33 kDa peptides including seven mammalian 
isoforms (α/β, γ, σ, ε, ζ, η, and θ/τ), which regulate multiple cellular functions via 
interactions with intracellular proteins by phosphoserine and phospho-threonine 
binding. Each protein is encoded by a gene belonging to the family of tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein (YWHA). 14-3-3 
proteins can regulate cancer cell proliferation, survival, migration/invasion, and 
function. Five members of 14-3-3 family proteins (α/β, γ, σ, ε, and ζ) may be involved 
in the HCC progression, including tumor growth, metastasis, and resistance to 
sorafenib, however, the functions and clinical significances of 14-3-3θ/τ and 14-3-3 η 
(i.e., 14-3-3 protein eta, encoded by YWHAH) in HCC are poorly known. Here, Shen 
et al. show that the 14-3-3η-ERK1/2 pathway promotes HCC, not only by acting in 
tumor cells but also in tumor vessels. Moreover, 14-3-3η may be a potential 
therapeutic target for HCC and a biomarker for predicting sorafenib treatment 
response. 
Liver graft injury and tumor recurrence are major challenges in patients who receive a 
liver transplant for HCC. In the context of liver graft injury, recruitment of regulatory T 
cells (Tregs) leads to late phase tumor recurrence after liver transplantation. However, 
the mechanisms for recruitment of Tregs is unknown. Li et al. now report that, at liver 
graft injury, the C-X-C motif chemokine 10 (known as IP-10; encoded by CXCL10) 
and its receptor CXC-R3 are overexpressed; enhanced IP-10 signaling leading to 
recruitment of Tregs. Future studies should elucidate the mechanisms for IP-10 
overexpression at the site of liver injury. 
Type 1 IFNs signal through a common heterodimeric receptor (IFNAR1/IFNAR2) or 
through IFNAR1 alone to induce hundreds of ISGs. Receptor engagement results in 
the activation of “canonical” signaling pathways involving JAK1 and TYK2 kinases that 
phosphorylate STAT1 and STAT2 transducers, which then associate with IRF9 to form 
the ISGF3 complex, which induces transcription of antiviral effectors (OAS, IFIT, MX, 
or GBP families). However, type 1 IFNs also activate several “non-canonical” signaling 
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pathways, e.g., other STAT family members such as STAT3, PI-3K, the mTOR-Akt-
S6K axis. The role of “non-canonical” signaling pathways is incompletely understood; 
they are thought to play a crucial role in the induction of the inflammatory and anti-
tumoral action of type 1 IFNs. Brisac et al. now identify a novel “non-canonical” 
signaling pathway used by type 1 IFNs in hepatoma cells. They find that following 
IFNAR engagement, the IQ-motif containing GTPase activating protein 2 
physically interacts with the transcription factor p65 of the NF-κB family to 
induce a subset of anti-viral ISGs (e.g., MX1, RSAD2, EIF2AK2), independently of 
the “canonical” JAK/STAT pathway. These intriguing findings suggest that type 1 
IFNs can use “non-canonical” signaling to induce antiviral effectors and for this reason 
deserve to be confirmed in cells other than hepatoma cells. 
The presence of PVTT in patients with HCC indicates an advanced stage, and liver 
resection is not recommended. Kokudo et al. evaluated survival associated with liver 
resection in a series of 6,474 patients with HCC and PVTT by analyzing data from a 
Japanese nationwide survey. They show that as long as the PVTT is limited to the 
first-order branch, liver resection is associated with a longer survival outcome 
than non-surgical treatment. 
 
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). 
NGAL as an inflammatory mediator, preserved hemostatic status in NAFLD  
The molecular mechanisms that mediate inflammation in patients with non-alcoholic 
steatohepatitis (NASH) are not well known. In this issue, Dewei et al. investigated the 
role of neutrophil gelatinase-associated lipocalin (NGAL, encoded by LCN2), a known 
biomarker of acute kidney injury in humans that also acts as a pro-inflammatory 
cytokine. The authors showed that NGAL hepatic expression and serum levels 
were increased in patients and in rodents with NASH. Importantly, infiltration of 
neutrophils and macrophages were attenuated in mice lacking Lcn2. In contrast, 
administration of NGAL exacerbated diet-induced liver injury, inflammation and 
macrophage accumulation. The effects of NGAL were mediated by CXCR2. This 
translational study suggests that NGAL could be a potential therapeutic target to 
attenuate inflammation in patients with NASH. 
NAFLD is associated with an increased risk of thrombosis, yet the mechanisms are 
largely unknown. In this issue, Potze et al. investigated whether hypercoagulability 
contributes to this risk. The authors performed an in depth hemostatic profile in a cohort 
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of patients with NAFLD and both lean/overweight and diseased controls. Platelet 
activation markers, thrombomodulin-modified thrombin generation and 
thromboelastography test were comparable between patients with non-cirrhotic 
NAFLD and controls. Plasma fibrinolytic potential and clot permeability were 
decreased in overweight controls and noncirrhotic NAFLD. This study reveals that the 
overall hemostatic profile is comparable between patients with non-cirrhotic NAFLD 
and controls. Interestingly, prothrombotic features in patients with NAFLD are 
likely driven by obesity.  
 
ALCOHOLIC LIVER DISEASE. 
Daily alcohol intake at the population level predicts the weight of alcohol 
cirrhosis  
Most studies assessing alcohol as a cause of cirrhosis at the population level focus on 
per capita consumption. In this issue, Stein et al. performed a comprehensive analysis 
of the WHO 2014 Global Status Report on Alcohol and Health and countries were 
categorized based on daily consumption. The WHO 2014 Report found that half of 
cirrhosis mortality worldwide is attributable to alcohol. The designation of 
countries by moderate or heavy daily drinking had the strongest influence on the 
weight of alcohol in the cirrhosis burden. Importantly, drinking patterns and the type of 
alcohol did not independently predict the weight of alcohol as a cause of cirrhosis. This 
study strongly suggest that reducing heavy drinking should be considered as an 
important target for public health policies to reduce the burden of alcoholic cirrhosis. 
 
VIRAL HEPATITIS  
Late viral hepatitis diagnosis – a “missed opportunity”, Molecular mechanisms 
of HBV-induced hepatocarcinogenesis 
Timely and effective care to people chronically infected with hepatitis B (HBV) and C 
virus (HCV) infection is essential to prevent clinical endpoints and to reduce the rising 
burden of liver disease, whereas late hepatitis notification may increase the risk of 
advanced liver disease complications, including decompensated cirrhosis and 
hepatocellular carcinoma (HCC). The large population-based study by Alavi et al. 
linked HBV/HCV notifications in 1995-2012 to cancer registry and hospital admissions 
in New South Wales, Australia between 1995-2012 in 50,958 HBV- and 79,727 HCV-
infected individuals. Although the percentage of both, late HBV and HCV 
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notifications declined in more recent years - which can be taken as an indicator of 
enhanced viral hepatitis screening - still 17-29% of the population were diagnosed 
late, defined as either after, at the time, or within two years before disease 
decompensation or HCC development. The results of this elegant population-based 
study shows the importance to improve our screening strategies and linkage to care 
early in the chronic course of the infection 
Hepatic cancer stem cells (hCSCs) detected in liver cancers of various etiologies are 
characterized by expression of certain cell surface markers like among others the 
epithelial cell adhesion molecule (Ep-CAM), prominin-1 (also known as CD133), and 
CD44 antigen. Their presence may define a certain subset of HCCs with poor 
prognosis and resistance to sorafenib and therefore provide a new prognostic tool for 
precise HCC classification. The study by Mani et al. nicely describes a novel 
molecular mechanism by which HBV generates the expression of an hCSC-like 
gene signature. Since the expression of the hCSC-like gene signature in HBV 
replicating cells and X/c-myc liver tumors was mediated by Ep-CAM regulated 
intramembrane proteolysis and Wnt pathway activation, inhibition of these pathways 
could serve as potential therapeutic strategies for this subtype of HBV-associated 
HCCs. 
 
CIRRHOSIS 
Novel therapeutic approach to sarcopenia and new insight into pathogenesis, 
biomarkers and novel therapeutic targets for cirrhosis 
Sarcopenia is a dreadful complication of cirrhosis and is an independent predictor of 
mortality. The mechanisms underlying its pathogenesis are poorly understood and 
there are no specific therapies. Two papers in the present issue of the Journal address 
this issue. Sinclair et al. describe the results of the first and important randomized 
controlled clinical trial comparing testosterone with placebo in male cirrhotic patients 
with low testosterone. The data provide clear evidence that administration of 
testosterone is safe and is associated with an improvement in muscle and bone 
mass and, a reduction in fat mass and HbA1c. Another paper in this issue 
addresses possible pathophysiologic mechanisms underlying sarcopenia. Davuluri et 
al. provide solid evidence for a novel hypothesis linking sarcopenia, 
hyperammonemia and reduction in protein synthesis. They suggest that L-
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leucine may rescue protein synthesis that is inhibited by ammonia. New 
therapeutic targets for sarcopenia are identified in this paper. 
Prognostic criteria defining outcome of cirrhotic patients is currently based on a 
collection of clinical and biochemical variables, which are not direct targets of therapy. 
There are 3 highly relevant papers in the present issue of the Journal that highlight 
pathophysiological markers that may be usable as potential therapeutic targets, while 
maintaining their prognostic ability. Kalambokis et al. provide exciting new data in 
cirrhotic patients with thrombocytopenia indicating that they are 
hypercoagulable and that vWF-Ag and FVIII-to-PC ratio independently predicts 
decompensation providing a new therapeutic target.  
Circulatory dysfunction is closely correlated with poor clinical outcome of cirrhotic 
patients. Vasopressin is increased in cirrhotic patients but its role is difficult to study 
because of its short half-life and methodological issue with its measurement. Copeptin 
is stable and released stoichiometrically with vasopressin. Sola et al. show that 
plasma copeptin levels accurately identifies cirrhotic patients at risk of dying 
and then validate their results in an independent cohort. Their data may allow 
development of copeptin as a companion biomarker to identify patients likely to benefit 
from aquaretics.  
At present, cirrhotic patients require screening endoscopy at regular intervals to 
identify those at risk of bleeding. The Baveno VI guidelines propose that cirrhotic 
patients with a liver stiffness measurement (LSM) <20kPa and a platelet count 
>150000/μL can avoid screening endoscopy but this guideline has not been validated 
independently. In an important study, Maurice et al. studied over 300 patients and 
showed an accuracy of about 98% confirming the validity of the Baveno 
proposal. This observation has the potential to avoid unnecessary endoscopies. 
 
